Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950518 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL13955293 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL3534298 | 0.81 | SMN1; SMN2 (0.48) | ALDH1A1KMT2AMEN1TAS1R3TAS1R1 | |
| SCHEMBL13499143 | 0.79 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL2560483 | 0.76 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL4337300 | 0.76 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL7478331 | 0.76 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL12932008 | 0.76 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL1472540 | 0.76 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL13936482 | 0.74 | MEN1 (0.41) | ALDH1A1KMT2AMEN1MAPTTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | disclosed |
| US-7393852-B2 | Piperazine derivatives and methods of use | AMGEN INC. (US) | 2008-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | ALDH1A1 184/4885KMT2A 2982/4885MEN1 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.